CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 128 enrolled
Drug / intervention
Intravitreal aflibercept injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02462889
NCT02462889Phase 2Completed
CompareCT.gov

A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes

Jeffrey S Heier·interventional·Posted Jun 4, 2015·Updated Nov 14, 2025

In Brief

A Phase 2 clinical trial evaluating Intravitreal aflibercept injection and Placebo for Age-Related Macular Degeneration. Completed, enrolled 128 participants across 4 sites.

Detailed Summary

This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk" subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 4, 2015
Enrollment StartJun 1, 2015
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.1 years ago

Interventions

Intravitreal aflibercept injectiondrug

Intravitreal aflibercept injection

Placebodrug

Sham injection